Vor-Wordmark-RGB-FullColor-070920.png
Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT
October 19, 2021 07:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the presentation of data from its novel...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management
October 12, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as...
Vor-Wordmark-RGB-FullColor-070920.png
VOR33 Granted U.S. FDA Fast Track Designation for AML
September 09, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that the U.S. Food and Drug Administration...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Participate in Three Upcoming Investor Conferences
September 02, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today announced that the Company will be participating in...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Reports Second Quarter 2021 Financial Results and Provides Company Update
August 09, 2021 16:05 ET | Vor Biopharma
On track to report initial VOR33 clinical data in the first half of 2022Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignanciesInitiated...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
July 08, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with...
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs
June 17, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company) announced today that it will build-out an in-house clinical manufacturing facility in Cambridge,...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp
June 11, 2021 08:00 ET | Vor Biopharma
Mr. Patterson brings nearly 30 years of senior leadership experience in biotechnology, including leading Audentes Therapeutics from inception through acquisition over an eight-year periodKush M....
Vor-Wordmark-RGB-FullColor-070920.png
Vor to Develop Multi-Targeted CAR-Ts with Abound Bio
June 10, 2021 08:00 ET | Vor Biopharma
CAMBRIDGE, Mass. and PITTSBURGH, June 10, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR) and Abound Bio today announced they have entered into a multi-year strategic collaboration and license...
Vor-Wordmark-RGB-FullColor-070920.png
Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences
May 25, 2021 16:10 ET | Vor Biopharma
CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with...